Navigation Links
PRA SPEAKING EVENT: Phase I Studies with Hepatitis C Compounds in Healthy Volunteers and Patients: Views from Inside
Date:4/8/2009

RALEIGH, N.C., April 8 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces Dr. Andre van Vliet, Vice President of Medical Affairs - Early Development Services (EDS), will host an audio conference on the development of New Chemical Entities (NCEs) in the treatment of hepatitis C. This interactive session will take place on April 14, 2009 at 11:30 am (ET). Drawing on his 19 years of experience in this field, Dr. van Vliet will provide an inside look at opportunities and obstacles when developing a hepatitis C compound including critical steps to optimize the success potential of an NCE as well as pitfalls and obstacles.

Dr. Andre van Vliet is a Board Certified internist, with expertise and training in oncology and clinical Pharmacology. His published materials include a recent article for the American Gastroenterological Association Institute on hepatitis C. Since 1995, he has supervised all aspects of Phase I and IIa drug research for PRA's EDS group.

With 228 beds in Europe and the U.S., and an innovative Phase I model that brings the center to the patients in Central/Eastern Europe, PRA's EDS group provides comprehensive services for Phase I and Phase IIa studies. In the Netherlands, PRA EDS initiated the "Dutch Hepatitis Research Initiative." In this unique research collaboration, PRA EDS collaborates with the Amsterdam Medical Centre and the Rotterdam Erasmus Medical Centre. In PRA's Product Registration group (Phase II and III), over a third of its project management and clinical operations employees are experienced in infectious diseases clinical research.

The deadline for registration is Monday, April 13, 2009. To learn more about the audio conference, click http://www.prainternational.com/portal/page/portal/PRAINTL/News%20%20Events/Events/Popup. To register, clickhttp://www.fxconferences.com/Phase-I-Studies-with-Hepatitis-C-Compounds-in-Healthy-Volunteers-and-Patients-Views-from-Inside-P317.aspx

About PRA International

PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Infectious Diseases, Oncology, CNS, Respiratory/Allergy and Cardiovascular, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PRA International Speaking Event: Beyond Global Feasibility
2. PRA International Speaking Event: Rational Drug Design and Development in Infectious Diseases
3. Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says
4. First Nationwide Folic Acid Survey of Spanish-Speaking Women Finds Most Are Missing Benefits, March of Dimes Says
5. Newport Introduces More Resources for Spanish Speaking Plan Participants
6. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
7. When it comes to abstinence teens, adults arent speaking the same language
8. Children in non-English-speaking households face many health disparities, researcher concludes
9. Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
10. Speaking of Womens Health Gives the Gift of Knowledge and Good Health This Mothers Day
11. Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Southland ... line of classic American timber frame barn kits, which can be found on its ... inspired by historic American barn plans, and they highlight the craftsmanship of timber post ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke survivors ... sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics had ... with hemiplegia due to stroke. , Ekso Bionics has now received clearance from the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
Breaking Medicine Technology: